Abstract
The indications for tumor-mass reduction surgery and subsequent immunotherapy in patients with stage IV hepatocellular carcinoma (HCC) were elucidated in this study. About 42% of the resected specimens from stage IV-A patients (n=26) contained well-differentiated multicentrically occurring HCC, which was not found in any of the stage IV-B patients (n=9). The 2-year survival rate after reduction surgery was 49% for the stage IV-A patients and only 13% for the stage IV-B patients, while 6 of the stage IV-A patients who survived for more than 2 years had no vascular invasion or distant organ metastases. Some of the stage IV patients maintained normal peripheral natural killer (NK) activity and were also able to tolerate surgical insults immunologically, provided that appropriate postoperative immunotherapy was given. Thus, stage IV-A HCC has a greater possibility of containing slow-growing intrahepatic tumor clusters, and the removal of any rapidly growing tumors from among these should be undertaken by reduction surgery followed by subsequent multidisciplinary treatment for residual tumor cells, including appropriate immunotherapy.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
UICC International Union Against Cancer (1982) Liver (ICD-O 155). In: Hermanek P, Sobin LH (eds) TNM classification of malignant tumours, 4th edn. Springer, Berlin Heidelberg New York, pp 53–55
Berke G (1989) Functions and mechanisms of lysis induced by cytotoxic T lymphocytes and natural killer cells. In: Paul WE (ed) Fundamental immunology, 2nd edn. Raven New York, pp 735–764
Berman C (1958) Primary carcinoma of the liver. Adv Cancer Res 5:55–96
Higgins GK (1970) The pathologic anatomy of primary hepatic tumors. In: Pack GT, Islami AH (eds) Tumor of the liver. Berlin Heidelberg New York, pp 15–37
Sakamoto M, Hirohashi S, Tsuda H, Shimosato Y, Makuuchi M, Hosoda Y (1989) Multicentric independent development of hepatocellular carcinoma revealed by analysis of hepatitis B virus integration pattern. Am J Surg Pathol 13:1064–1067
Arakawa M, Kage M, Sugihara S, Nakashima T, Suenaga M, Okuda K (1986) Emergence of malignant lesions within an adenomatous hyperplastic nodule in cirrhotic liver. Gastroenterology 91:198–208
Yamamoto Y, Iizuka H, Yamamoto M, Tasaka K, Sugahara K (1990) A proposal of effective immunochemotherapy using recombinant interleukin 2 and Adriamycin, and its theoretical background. Yamanashi Med J 5:25–34
Whiteside T, Herberman RB (1989) The role of natural killer cells in human disease. Clin Immunol Immunopathol 53:1–23
Japan Liver Cancer Study Group (1989) The general rules for the clinical and pathological study of primary liver cancer. Jpn J Surg 19:98–129
Talmadge JE, Herberman RB (1986) The preclinical screening laboratory: Evaluation of immunomodulatory and therapeutic properties of biological response modifiers. Cancer Treat Rep 70:171–182
Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White MS (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activited killer cells and Interleukin-2 or high dose IL2 alone. N Engl J Med 316:889–897
Fujimoto S, Takada M, Araki K, Hamasato S, Maeda N, Ohtsuki Y, Sonobe H (1990) Tumor immunotherapy using specific cytotoxic T lymphocytes (CTL) (in Japanese). Taisha (Metabolism and Disease), Immunology 1990, 27:141–153
PaiIizuka H, Yamamoto M, Kohno T, Yamamoto Y, Tasaka Y, Sugahara K (1991) Continuous infusion of IL-2 and intermittent Adriamycin injections selectively to advanced hepatocellular carcinoma through the irrigating hepatic artery. In: Tsuchiya M, Nagura H, Hibi T, Moro I (eds) Frontiers of mucosal immunology, vol 2. Elsevier, Amsterdam, pp 513–516
Esumi M, Aritaka T, Arii M, Suzuki K, Tanikawa K, Mizuno H, Mima T, Shikata T (1986) Clonal origin of human hepatoma determined by integration of hepatitis B virus DNA. Cancer Res 46:5767–5771
Kenmochi K, Sugihara S, Kojiro M (1987) Relationship of histologic grade of hepatocellular carcinoma (HCC) to tumor size, and demonstration of tumor cells of multiple different grades in single small HCC. Liver 7:18–26
Hedley DW, Fliedlander ML, Tailor IW, Rugg CA, Musgrove EA (1983) Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow-cytometry. J Histochem Cytochem 31:133–1335
Prior C, Kathrein H, Mikuz G, Judmaier G (1988) Differential diagnosis of malignant intrahepatic tumors by ultrasonically guided fine needle aspiration biopsy and by laparoscopic/intraoperative biopsy. A comparative study. Acta Cytol 32:892–895
Pross HF, Baines MG (1987) Alterations in natural killer cell activity in tumor-bearing hosts. In: Herberman RB, Wiltrout RH, Gorelik E (eds) Immune Responses to Metastases, vol 1. CRC, Boca Raton, pp 57–78
Morizane T, Watanabe T, Tsuchimoto K, Tsuchiya M (1980) Impaired T cell function and decreased natural killer activity in patients with liver cirrhosis and their significance in the development of hepatocellular carcinoma. Gastroenterol Jpn 15:226–232
Dunk AA, Novick D, Thomas HC (1987) Natural killer cell activity in hepatocellular carcinoma. In vitro and in vivo response to Interferon. Scand J Gastroenterol 22:1245–1250
Harafuji H, Kakumu S, Fuji A, Ohtani Y, Murase K, Tahara H (1987) Natural killer and activated killer activities in chronic liver disease and hepatocellular carcinoma: Evidence for a decreased lymphokine-induced activity of effector cells. Clin Exp Immunol 68:348–356
Lee CS, Lee FZ (1989) Natural killer cell activity in hepatocellular carcinoma patients. J Formosan Med Assoc 88:478–482
Yao EH, Li D, Gu H (1984) T cell subpopulation in hepatoma. Am J Gastroenterol 79:227–228
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yamamoto, M., Iizuka, H., Matsuda, M. et al. The indications for tumor mass reduction surgery and subsequent multidisciplinary treatments in stage IV hepatocellular carcinoma. Surg Today 23, 675–681 (1993). https://doi.org/10.1007/BF00311704
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00311704